BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
UBS maintains buy on Ranbaxy
Ranbaxy will benefit from strong outlook for Sun Pharma. Stock continues to trade at a discount to Sun Pharma. The merger is expected to close by the end of 2014 calendar year. Near term business remains weak.